Veria - Claim Fact Check

Claim: The United States Food and Drug Administration has a special relationship with Tucker Carlson and his nicotine company

40%

Based on my research, I found no relevant claims in the fact-checking database. However, I was able to find information through web searches about Tucker Carlson's nicotine company ALP and its relationship with the FDA.

Analysis of the claim:

Tucker Carlson launched a nicotine pouch company called ALP in partnership with Turning Point Brands¹²
The FDA initiated a pilot program in September 2025 to fast-track PMTA (Premarket Tobacco Product Application) decisions for select nicotine pouch brands¹³²
Turning Point Brands (Carlson's manufacturing partner) was included in this pilot program alongside three other major tobacco companies: Philip Morris International, Altria, and Reynolds American³⁴²
The fast-track program aims to complete reviews by December 2025 and was launched amid pressure from the Trump administration to speed up approvals and clear regulatory backlogs⁴²³
When asked if he spoke to administration officials (such as HHS Secretary RFK Jr. or Vice President JD Vance, who employs Carlson's son) to expedite the application, Carlson stated "no"⁵
ALP has faced scrutiny for alleged FDA violations during the approval process, including failing to include required nicotine warnings in social media advertising and implying endorsements by government officials¹

Key Considerations:

The pilot program includes multiple major tobacco companies, not just Turning Point Brands/ALP²³
The expedited review appears to be part of a broader Trump administration policy to accelerate nicotine pouch approvals generally, rather than specific preferential treatment for Carlson's company⁴²³
Carlson himself has expressed hostility toward the FDA, stating "We shouldn't need FDA approval" and calling FDA officials "douchebags"⁶
The inclusion in the pilot program does not mean exemption from federal tobacco laws or guaranteed approval¹

Overall validity: 40%

While Tucker Carlson's nicotine company was included in an FDA fast-track pilot program alongside other major tobacco companies, characterizing this as a "special relationship" is misleading. The expedited review process appears to be the result of general Trump administration pressure on the FDA to speed up approvals industry-wide, not specific preferential treatment for Carlson. Additionally, Carlson has been openly critical of the FDA and denies lobbying administration officials for special treatment.